Switching Between Ozempic and Wegovy: What the Evidence Actually Shows

What the semaglutide trials tell us about dose and indication

The clinical case for semaglutide in weight management rests on the STEP programme. STEP 1, published in the New England Journal of Medicine, ran for 68 weeks and found that adults using semaglutide 2.4mg weekly achieved around 15% average body-weight reduction, compared with around 2.4% in the placebo group. That 2.4mg maintenance dose is central: it is the dose Wegovy titrates towards, and it is higher than the maximum dose used in Ozempic for diabetes (1mg, or 2mg in some formulations). Ozempic's trials were conducted primarily in people with type 2 diabetes at doses selected for glycaemic control. The weight-loss evidence underpinning Wegovy's licence was built at doses that Ozempic's label does not routinely reach for its own indication. That difference matters when a prescriber decides whether your current regimen is actually doing the job Wegovy was designed to do. Dose equivalence on paper does not mean clinical equivalence in practice, and the titration schedule, starting point and monitoring needs may all shift depending on your medical history and what you have been taking previously.

Ozempic, Wegovy, and the UK licensing picture, not interchangeable

The NHS semaglutide medicines page sets this out plainly: Ozempic is prescribed for type 2 diabetes, and Wegovy is the licensed brand for weight management. Using Ozempic off-label for weight loss is not an appropriate private prescription from a regulated pharmacy, and any service offering it that way should be a serious concern. If you have been prescribed Ozempic for diabetes and have since been told you no longer need it, or if your diabetes management has changed, a conversation with your GP or prescriber about what happens next (including whether switching from Ozempic to Wegovy for weight loss is appropriate for you) is the right route. The differences between Wegovy and Ozempic go beyond the label on the box; the indication, the dose ceiling, the NICE criteria and the monitoring obligations are all distinct. NICE's appraisal of semaglutide for weight management, TA875, covers Wegovy specifically, within specialist weight management services, for eligible adults. No equivalent weight-loss NICE appraisal exists for Ozempic.

What switching actually involves, and a comparison of the two products

The practical question people ask is: if they are already on Ozempic, can they simply continue at the equivalent semaglutide dose under a Wegovy prescription? Sometimes the answer is yes in principle, though the process of switching from Ozempic to Wegovy requires a prescriber to review your current dose, your medical history and your indication before anything changes. It is not an admin exercise. Below is a factual comparison of the two products under their UK licences.

For those who want to explore how Wegovy and Ozempic compare across their respective clinical profiles, the distinction in dose ceiling is particularly relevant to weight outcomes. The 2.4mg Wegovy maintenance dose produced the weight-reduction results in STEP 1; the 7.2mg single-dose pen, approved by the MHRA on 14 April 2026, narrows the gap with tirzepatide in trials reporting around 20.7% average weight loss over 72 weeks. That is the trajectory the evidence supports, and it depends on being on the right medicine, at the right dose, under proper clinical oversight. People already using Wegovy who are wondering whether switching from Wegovy to semaglutide under a different brand or formulation is possible will find that the answer turns on dose, indication and prescriber oversight, not a simple brand swap. The NICE guidelines for Wegovy are worth reading if you want to understand what the NHS pathway requires. For people who fall outside NHS criteria or prefer not to wait, the private route through a regulated pharmacy like ours is the alternative, though you still need a valid prescription following proper clinical assessment. Which option suits your situation is a clinical decision our prescribers make with you.

At nume (no, at our pharmacy) a prescriber personally reviews your consultation before any prescription is issued. If you order before midday on a working day, approved treatment is dispatched the same afternoon. Plain packaging, tracked DPD delivery, no subscription. The free consultation is where it starts.